BerGenBio

Report Publication Announcement • May 14, 2018

BerGenBio participation at upcoming healthcare investor and life sciences industry conferences

BerGenBio participation at upcoming healthcare investor and life sciences industry conferences

Bergen, Norway, 14 May 2018- BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

multiple cancer indications, will be participating at the following upcoming

conferences.

· 14-16 May, Bio Euro quity Europe 2018 (Ghent, Belgium)*

· 23 May, ABG Sundal Collier Cancer Seminar (Stockholm, Sweden)*

· 1 June, Sachs Immuno-Oncology BD&L and Investment Forum (Chicago, IL)*

· 4 June, Norne Securities Conference (Bergen, Norway)*

· 1-5 June, 2018 Annual Meeting of the American Society of Clinical Oncology

(ASCO) (Chicago, IL)*? (more details to follow)

· 4-7 June, BIO Annual Convention (Boston, MA)

· 5-8 June, Jefferies Global Healthcare Conference (New York, USA)

Further details can be found on BerGenBio's website (www.bergenbio.com) in the

Media Centre / Events section.

*The slides and posters presented at these events will be made available on

BerGenBio's website in the Investors / Presentations section following the

presentations.

?BerGenBio will be hosting a reception on 2 June at The School of the Art

Institute Ballroom, Chicago, USA during which short presentations will be given

by clinical investigators participating in the bemcentinib clinical trials and

key opinion leaders in AXL biology. For more information, please visit

www.bergenbio.com/media-centre/events/.

-End-

About BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company focused on

developing a pipeline of first-in-class AXL kinase inhibitors as a potential

cornerstone of combination cancer therapy. The Company is a world leader in

understanding the essential role of AXL kinase in mediating aggressive diseases,

including immune evasive, drug resistance metastatic solid and haematological

cancers.

BerGenBio's lead product, bemcentinib (BGB324), is a selective, potent and

orally bio-available small molecule AXL inhibitor in four Company sponsored

Phase II clinical trials in major cancer indications, with read-outs anticipated

during 2018. It is the only selective AXL inhibitor in clinical development.

The Company sponsored clinical trials are:

· Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation driven non

-small cell lung cancer (NSCLC)

· Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the lung, and

· Bemcentinib with KEYTRUDA in triple-negative breast cancer (TNBC).

· Bemcentinib as a single agent and combination therapy in acute myeloid

leukaemia (AML) / myeloid dysplastic syndrome (MDS)

The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the

lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth,

NJ, USA), through a subsidiary.

In addition, a number of investigator-sponsored trials are underway, including a

trial to investigate bemcentinib with either MEKINIST® (trametinib) plus

TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial

combining bemcentinib with docetaxel in advanced NSCLC.

BerGenBio is simultaneously developing a companion diagnostic test to identify

patient subpopulations most likely to benefit from treatment with bemcentinib.

This will facilitate more efficient registration trials and support a precision

medicine based commercialization strategy.

The Company is also developing a diversified pre-clinical pipeline of drug

candidates, including BGB149, an anti-AXL monoclonal antibody.

For further information, please visit: www.bergenbio.com

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary

of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of

OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a

registered trademark of Novartis International AG and MEKINIST® is a registered

trademark of GSK plc.

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

International Media Relations

David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson

bergenbio@citigatedewerogerson.com

+44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.